Researchers in the Sunwoo Lab have developed a method to differentiate intra-epithelial innate lymphoid cells type 1 (ieILC1s) from conventional peripheral natural kills cells for immunotherapeutic purposes.
Histone acetyltransferase 1 (HAT1) is an enzyme which acetylates lysine on histone proteins and is intricately involved with regulating gene transcription.
Stanford researchers have developed a portable hybrid frame-event based near eye gaze tracking system that has a superior speed while using a lower data bandwidth. They demonstrated real time results for gaze-tracking.
The Bronte-Stewart lab has designed an algorithm for calculating neural activity burst duration to better manage closed loop deep brain stimulation in patients with Parkinson's disease.
Radiation therapy is a common option in diseases like breast cancer, but can also cause significant damage to the skin. Permanent scarring and fibrosis can result, with both aesthetic and functional consequences for cancer patients.
Stanford researches have formulated a robust database called PRECOG (Prediction of Clinical Outcomes from Genomics) that connects cancer genome expression and patient survival/outcomes in a more predictive and extensive collection than any other signature on the market.
Aging is associated with the decline of mitochondrial function, particularly in related metabolic diseases such as obesity, diabetes, and heart disease.
Researchers in Prof. Michael Lin's laboratory have developed a viral-based cancer therapy platform that could be used for targeting treatment to cancer cells with aberrant signaling in EGFR or HER2 pathways.
Researchers at Stanford have developed prodrug derivatives of protein kinase C (PKC) modulators that have lower toxicity and are more effective than the parent compound. PKC modulators are being developed to treat a variety of diseases.
Researchers at Stanford have developed humanized therapeutic antibodies to treat cancers, particularly melanoma, inflammatory disorders such as sarcoidosis and skin and organ fibrosis.
Stanford researchers have discovered that dietary metabolites, specifically alpha-ketoglutarate, are able to delay retinal degeneration to treat blinding retinal diseases regardless of the type of retinal condition.